NEW YORK - Bruker said today in a filing with the US Securities and Exchange Commission that it expects Q2 2020 revenues of around $420 million to $425 million.
That figure would represent a decline of 13 percent to 14 percent from $490 million in Q2 2019 but would beat analysts' average estimate of $388.8 million.
Bruker had previously projected a year-over-year revenue decline of between 15 percent and 25 percent for the quarter.
The Billerica, Massachusetts-based company said that the better-than-expected projections were driven mainly by stronger demand for its life science products.